Eurofins Scientific Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St · 03/01 06:15

Eurofins Scientific (EPA:ERF) Full Year 2024 Results

Key Financial Results

  • Revenue: €6.95b (up 6.7% from FY 2023).
  • Net income: €356.3m (up 39% from FY 2023).
  • Profit margin: 5.1% (up from 3.9% in FY 2023).
  • EPS: €1.87 (up from €1.33 in FY 2023).
revenue-and-expenses-breakdown
ENXTPA:ERF Revenue and Expenses Breakdown March 1st 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Eurofins Scientific EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 20%.

The primary driver behind last 12 months revenue was the Europe segment contributing a total revenue of €3.60b (52% of total revenue). Notably, cost of sales worth €5.39b amounted to 78% of total revenue thereby underscoring the impact on earnings. The most substantial expense, totaling €541.5m were related to Non-Operating costs. This indicates that a significant portion of the company's costs is related to non-core activities. Explore how ERF's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.

Performance of the market in France.

The company's shares are down 1.0% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 2 warning signs for Eurofins Scientific you should be aware of.